Calidad de vida relacionada con la salud tras terapia anti-factor de necrosis tumoral alfa en pacientes con artritis reumatoide. Un estudio piloto

Medina, Gracia María Abalos; Villaverde, G. Ruíz; Cano, Daniel Sánchez; Villaverde, Ricardo Ruíz; Rodrigo, Jesús Ramírez; Álvarez, Enrique Raya; Gutiérrez, Carmen Villaverde

doi:10.1016/j.reuma.2010.06.004

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such an observation highlights the need for long-term studies, in order to assess whether improvement gained is sustained and to what extent. Findings from this study are in accordance with results obtained from the generic SF-36 questionnaire in a study conducted on a Spanish population [20]. Findings from both HRQOL questionnaires used indicate the clinical effectiveness of TNF- α antagonists in achieving a better QOL, as documented in various studies [20, 21].…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Cost Effectiveness of TNF-αInhibitors in Rheumatoid Arthritis

Said

Coleiro²,

Adami³

et al. 2013

International Journal of Inflammation

View full text Add to dashboard Cite

Background. TNF-α inhibitors have shown to be effective in reducing disease activity and improving the quality of life. Due to the high costs associated with acquisition of this treatment, this study was undertaken to evaluate the ICER of TNF-α antagonists (etanercept, adalimumab, and infliximab) in improving the quality of life. Methods. The HAQ and SF-36 were administered at phases 1, 2, and 3, in order to assess the improvement in the QOL. Suppression of disease activity was assessed through the DAS-28. Results. Statistically significant improvements (P < 0.05) were noted for the SF-36 and HAQ after 3 months and for the DAS-28 after 6 months of TNF-α inhibitor therapy. The mean ICER per 10% improvement in the HAQ, DAS-28, and SF-6D were €1976.5, €2086.5, and €2316.4, respectively, following 6 months of TNF-α intervention. Most favorable ICERs were reported from a patient who had to undergo surgical intervention whilst on DMARD therapy. Conclusion. Significant improvement was observed in patients' quality of life, after a short timeframe of 6 months. Such data is useful information in the light of convincing policy makers, in terms of providing access to the medications to individual patients on national health service schemes.

show abstract

Section: Discussionsupporting

confidence: 90%

“…ACR/EULAR remission (<2.6) was met by 15.4% ( n = 2) of subjects. Abalos Medina [20] reported a higher prevalence of ACR/EULAR remission, yet this must be interpreted in the light of the limited number of participants and length of the current study.…”

Section: Discussionmentioning

confidence: 82%